# Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares (KNSA)

> Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares (KNSA) trades at $95.98 (+2.88%) as of 3:58:23 PM EST on Nov 4, 2026, +24.50% over the past month. Market cap is $7.33B, with 6.8 days to cover in short interest.

Canonical: https://massive.com/quote/knsa
Data as of: 2026-11-04T20:58:23.535Z (15-minute delayed)
Source: Massive (https://massive.com/docs/llms.txt)

## Price

**$95.98** +2.69 (+2.88%)
As of 3:58:23 PM EST on Nov 4, 2026 · 15-minute delayed
Nasdaq · usd

## Stock performance

How Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares (KNSA) stock has performed from one day to one year, with its 52-week range.

| Period | Return |
| --- | --- |
| 1D | +2.88% |
| 1W | +0.84% |
| 1M | +24.50% |
| YTD | +132.68% |
| 1Y | +145.22% |
| 52-wk range | $37.02 – $98.48 |

From daily closes through Nov 4, 2026.

## Key statistics

Today's trading snapshot for KNSA: day range, open, previous close, volume and market cap.

| Measure | Value |
| --- | --- |
| Day range | $91.74 – $96.28 |
| Open | $93.63 |
| Prev close | $93.29 |
| Volume | 730.03K |
| Market cap | $7.33B |
| Shares out | 48.84M |

## Valuation and profitability ratios

Valuation and profitability ratios for Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares: P/E, P/S, P/B, ROE and more.

| Measure | Value |
| --- | --- |
| P/E | 66.90 |
| P/S | 7.75 |
| P/B | 10.32 |
| P/FCF | 37.17 |
| ROE | 15.4% |
| ROA | 11.1% |
| Debt/Equity | 0.15 |
| Div yield | 0.00% |

As of Nov 3, 2026

## Insider trading

[Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares (KNSA) insider trading](https://massive.com/quote/knsa/insider-trading.md): open-market Form 4 buys and sells by Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares insiders over the last 12 months.

## 8-K filings

Material corporate events Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares has disclosed to the SEC on Form 8-K.

- Oct 27, 2026 · [Quarterly earnings](https://massive.com/quote/sec-filings/8-k/earnings-releases.md)
  “On October 27, 2026, Kiniksa Pharmaceuticals International, plc issued a press release announcing financial results for the quarter ended September 30, 2026.”
- Oct 22, 2026 · Executive compensation change
  “In addition, effective January 1, 2027, the Committee approved increases in Mr. Moat's annual base salary and annual target bonus to $700,000 and 60% from $650,000 and 55%, respectively.”
- May 29, 2026 · Annual meeting results
  “On May 29, 2026, Kiniksa Pharmaceuticals International, plc (the "Company") held its Annual Meeting of Shareholders (the "Annual Meeting") at which a quorum was present... The following are the voting results for the proposals considered and voted upon at the Annual Meeting, all of which were described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on April 6, 2026. Each proposal below was duly passed by the Company's shareholders at the Annual Meeting.”
- May 1, 2026 · [Executive officer departure](https://massive.com/quote/sec-filings/8-k/executive-departures.md)
  “On April 30, 2026, Eben Tessari informed Kiniksa Pharmaceuticals International, plc (the "Company") of his decision to resign as Chief Strategy Officer of the Company to pursue another executive position within the life sciences industry. Mr. Tessari will leave the Company on May 15, 2026.”
- Jan 14, 2026 · Executive officer appointment
  “Effective January 10, 2026, the Board of Directors of Kiniksa Pharmaceuticals International, plc (the "Company") appointed Ross Moat to the position of Chief Operating Officer and principal operating officer. Following the appointment, Mr. Moat will continue to oversee the Company's commercial operations, in addition to functional operations under the Chief Operating Officer title.”

## KNSA short interest

How heavily KNSA is shorted: shares short, days to cover and average daily volume.

| Measure | Value |
| --- | --- |
| Days to cover | 6.8 |
| Short interest | 3.76M |
| Avg volume | 555.48K |

As of Oct 15, 2026 · reported to FINRA twice monthly.

## KNSA news

The latest news and headlines about Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares (KNSA).

- [Here's Why Kiniksa Pharmaceuticals International, plc (KNSA) is a Strong Momentum Stock](https://www.zacks.com/stock/news/3022998/here-s-why-kiniksa-pharmaceuticals-international-plc-knsa-is-a-strong-momentum-stock?cid=CS-ZC-FT-fundamental_analysis|zacks_education_momentum_score-3022998) · Zacks Investment Research · Nov 4, 2026 · positive sentiment
- [Breakfast News: We’re Right There With You](https://www.fool.com/investing/breakfast-news/2026/11/02/breakfast-news/?source=iedfolrf0000001) · The Motley Fool · Nov 2, 2026 · neutral sentiment
- [Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution](https://www.globenewswire.com/news-release/2026/07/28/3334131/0/en/Kiniksa-Pharmaceuticals-Reports-Second-Quarter-2026-Financial-Results-and-Recent-Portfolio-Execution.html) · GlobeNewswire Inc. · Jul 28, 2026 · positive sentiment
- [Why Kiniksa Pharmaceuticals International Stock Raced Nearly 24% Higher Today](https://www.fool.com/investing/2026/04/28/why-kiniksa-pharmaceuticals-international-stock-ra/?source=iedfolrf0000001) · The Motley Fool · Apr 28, 2026 · positive sentiment
- [Kiniksa Pharmaceuticals Announces U.S. Orphan Drug Designation for KPL-387 for the Treatment of Pericarditis](https://www.globenewswire.com/news-release/2025/10/17/3168566/0/en/Kiniksa-Pharmaceuticals-Announces-U-S-Orphan-Drug-Designation-for-KPL-387-for-the-Treatment-of-Pericarditis.html) · GlobeNewswire Inc. · Oct 17, 2025 · positive sentiment

## About Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares

Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.

| Measure | Value |
| --- | --- |
| Exchange | Nasdaq |
| Market | stocks |
| Type | CS |
| Currency | USD |
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 366 |
| Listed | May 24, 2018 |

[Company website](https://www.kiniksa.com)

## FAQ

### What is the Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares (KNSA) stock price today?

Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares (KNSA) is trading at $95.98 (+2.88% on the day) as of 3:58:23 PM EST on Nov 4, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

### What is Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares?

Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases.

### What is the short interest in KNSA?

As of Oct 15, 2026, KNSA has 3.76M shares short and 6.8 days to cover.

### What exchange is KNSA listed on?

Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares (KNSA) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.

## Live data

Prices here are 15-minute delayed. For real-time KNSA quotes and the full history behind this page, use the Massive API or MCP server:

- `GET https://api.massive.com/v3/snapshot?ticker.any_of=KNSA`

Requests need a Massive API key. API reference for agents: https://massive.com/docs/llms.txt. Connect an AI agent through the Massive MCP server: https://massive.com/docs/ai-tools.

## Related

- [Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares (KNSA) insider trading](https://massive.com/quote/knsa/insider-trading.md)
- [SEC 8-K events](https://massive.com/quote/sec-filings/8-k.md)
- [Markets overview](https://massive.com/quote/index.md)

Nothing here is investment advice. Data and content are provided for informational purposes under the Massive Terms of Service: https://massive.com/terms